CD274 and cancer: Anti-PD-1 or anti-PD-L1 drugs are currently recommended for cancer patients based on PD-L1 detection in tumor or immune cells via IHC, microsatellite instability (MSI) detection via polymerase chain reaction, or mismatch repair deficiency detection via IHC45.